Priosh PharmaChem — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Priosh PharmaChem AG is a private, revenue-generating service provider founded in 2008 and headquartered in Zug, Switzerland. The company operates as a Contract Research and Manufacturing Organization (CRO/CMO), offering integrated services across the pharmaceutical value chain, including drug discovery, clinical trial management, API production, and formulation development. With seasoned industry leadership and strategic partnerships, such as with Shankus Hospitals, Priosh aims to reduce time-to-market for its clients' therapies while maintaining high quality and cost efficiency. Its business model is entirely service-based, positioning it as a partner rather than a drug developer with its own proprietary pipeline.

OncologyCNSCardiovascular

Technology Platform

Integrated service platform combining AI-enhanced drug discovery, clinical research (CRO/SMO), GMP API manufacturing, formulation development, and a specialized oncological biorepository. Focus on seamless, end-to-end client support from concept to commercial API.

Opportunities

The growing trend of pharmaceutical outsourcing, especially in complex therapeutic areas like oncology and CNS, presents a significant opportunity.

The company's unique integrated model and specialized oncological biorepository can attract clients seeking a streamlined, high-quality partner.

Expansion of its global network and AI capabilities could further enhance service efficiency and market reach.

Risk Factors

Revenue is entirely dependent on client projects, creating vulnerability to biotech funding cycles.

The company operates in a highly competitive CRO/CMO market with pressure on pricing and margins.

Execution risks, including potential quality issues or regulatory non-compliance in clinical or manufacturing services, could severely damage its reputation and financial stability.

Competitive Landscape

Priosh competes in the fragmented but competitive global pharmaceutical services sector, facing large public CROs (IQVIA, LabCorp, ICON) and CMOs (Lonza, Catalent) as well as numerous regional and niche players. Its differentiation is based on an integrated end-to-end model from a Swiss base, emphasizing quality, therapeutic expertise in oncology/CNS, and its unique biorepository asset. Competition on cost with providers in Asia and Eastern Europe remains a constant challenge.

More companies in Small Molecule Drugs →More companies in Switzerland →